openPR Logo
Press release

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

02-15-2017 02:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Janus Kinase

Janus Kinase (JAK) Inhibitors - Competitive Landscape,

MarketResearchReports.Biz presents this most up-to-date research on "Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017"

Description

DelveInsights, Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsights Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
Scope
The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors
The report provides the marketed drugs information including its sales, development activities and details of patent expiry
The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling
The report also gives the information of dormant pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Download Sample Copy of This Report at: http://www.marketresearchreports.biz/sample/sample/964543

Reasons to Buy
Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Content

Introduction
Introduction
Executive Summary
Executive Summary Snapshot
Janus kinase Inhibitors (JAK Inhibitors) Overview
Introduction
Structure and Mechanism
Janus Kinase Inhibitors
Types of JAK Inhibitors
Cytokines associated with Janus kinases and result of their mutations
JAK Inhibitors Market Analysis
Collaborations and Deals

Browse Latest Industry Press Release at: http://www.marketresearchreports.biz/pressreleases

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Contact
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 here

News-ID: 438716 • Views:

More Releases for Inhibitors

Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826 This latest report researches the industry structure,
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market. CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155 The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity. The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab